Infectious Diseases|Scientific research reagent|Beijing Key-Bio Biotech Co., Ltd.

Infectious Diseases

Product overview

This series of ELISA kits targets HIV and common sexually‑transmitted and blood‑borne pathogens. Core analytes include combined HIV antigen‑antibody assay, HIV‑1 P24 capsid antigen, HIV‑1 recent‑infection avidity assay, HIV‑1/2 differentiating antibodies, and Treponema pallidum‑specific antibodies. It is applicable to research scenarios such as epidemiological investigation of AIDS and sexually‑transmitted diseases, fundamental virological studies, analysis of biological characteristics of early‑stage HIV infection, and evaluation of transmission‑intervention effects. Adopted methodologies cover indirect ELISA, double‑antigen sandwich ELISA, double‑antibody sandwich ELISA and avidity ELISA. Test samples are mainly human serum and plasma, suitable for human serological in‑vitro research. For research use only. Not for in‑vitro diagnostic use.

Detailed introduction

1、HIV‑1 Recent‑Infection Avidity Rapid Assay Kit

· Product Profile:

HIV‑1 recent‑infection avidity rapid assay kit, designed to distinguish recent from long‑term HIV‑1 infection at population level and estimate HIV‑1 incidence rate in target groups. Suitable for AIDS sentinel surveillance, cross‑sectional epidemiological surveys and evaluation of intervention‑measure effectiveness.

This kit adopts the Limiting‑Antigen‑Avidity Enzyme‑Linked Immunosorbent Assay (LAg‑Avidity EIA). It detects the avidity level of anti‑HIV‑1 limiting‑antigen IgG antibodies in serum/plasma to distinguish recent HIV‑1 infection from long‑term infection at the population level, and is used to calculate the recent‑infection rate of specific populations. Compared with the conventional BED assay, the LAg‑Avidity assay is less affected by the immune status of infected individuals and viral subtypes, and features higher specificity and simple operation. It is applicable to multiple HIV‑1 subtypes. Globally, the LAg‑Avidity assay has gradually replaced the BED assay for HIV‑1 recent‑infection detection.

· Methodology:

Limiting‑Antigen Avidity Enzyme‑Linked Immunosorbent Assay (LAg‑Avidity EIA), ELISA platform, qualitative for population‑level epidemiological estimation only; not for individual clinical judgement.

· Sample & Format:

Sample type: human serum / plasma; 192‑test per kit (96T×2). Refer to manual for full details.

2、HIV‑1 P24 Antigen Detection Kit

· Product Profile:

HIV‑1 P24 antigen detection kit for research scenarios including life‑science research, basic and translational medical research, and pharmaceutical R&D (pharmacodynamic / toxicological evaluation).

· Methodology:

Double‑antibody sandwich ELISA, quantitative.

· Sample & Format:

75μL sample per reaction; 96‑test per plate. Refer to manual for full details.

3、HIV Combined Antigen‑Antibody Detection Kit

· Product Profile:

HIV combined antigen‑antibody detection kit for research scenarios including life‑science research, basic and translational medical research, and pharmaceutical R&D (pharmacodynamic / toxicological evaluation).

· Methodology:

Sandwich ELISA, qualitative.

· Sample & Format:

75μL sample per reaction; 96‑test per plate. Refer to manual for full details.

4、HIV 1+2 Antibody Detection Kit

· Product Profile:

HIV‑1/2 antibody detection kit for research scenarios including life‑science research, basic and translational medical research, and pharmaceutical R&D (pharmacodynamic / toxicological evaluation).

· Methodology:

Double‑antigen sandwich ELISA, qualitative.

· Sample & Format:

50μL sample per reaction; 96‑test per plate. Refer to manual for full details.

5、Treponema pallidum Antibody Detection Kit

· Product Profile:

Treponema pallidum antibody detection kit for research scenarios including life‑science research, basic and translational medical research, and pharmaceutical R&D (pharmacodynamic / toxicological evaluation).

· Methodology:

Double‑antigen sandwich ELISA, qualitative.

· Sample & Format:

50μL sample per reaction; 96‑test per plate. Refer to manual for full details.